Greasing the wheels of managing overweight and obesity with omega-3 fatty acids

Medical Hypotheses

Volumn 77, Issue 6, 2011, Pages 1114-1120

  Golub, N ^a   Geba, D ^a   Mousa, S A ^b   Williams, G ^a   Block, R C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOPAMINE; ENDOCANNABINOID; ICOSAPENTAENOIC ACID; LEPTIN; LINOLENIC ACID; NORADRENALIN; OMEGA 3 FATTY ACID;

APPETITE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY COMPOSITION; BODY FAT; BODY MASS; BRAIN DEVELOPMENT; BRAIN FUNCTION; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENERGY BALANCE; FISH; FOOD; FOOD AVAILABILITY; FOOD INTAKE; HIP; HUMAN; HUNGER; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS; ISCHEMIC HEART DISEASE; LIMBIC SYSTEM; METABOLISM; NONHUMAN; NUCLEUS ACCUMBENS; OBESITY; PREFRONTAL CORTEX; REINFORCEMENT; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; DISEASE MANAGEMENT; DOCOSAHEXAENOIC ACIDS; EATING; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; HUMANS; MODELS, BIOLOGICAL; OBESITY;

ANIMALIA;

EID: 80755139775     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.09.016     Document Type: Article

References (101)

1. de Moraes A.C., Fadoni R.P., Ricardi L.M., et al. Prevalence of abdominal obesity in adolescents: a systematic review. Obes Rev 2011, 12:69-77.
2. Misra A., Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008, 93:S9-S30.
3. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894:i-xii. World Health Organization (WHO), 1-253.
4. World Health Organization (WHO). Obesity and overweight. 2011. Accessed May 30, 2011 http://www.who.int/mediacentre/factsheets/fs311/en/.
5. Garrow J.S. Obesity and related diseases 1988, Churchill Livingstone, London.
6. Center for Health Statistics (NCHS). Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1976-80 through 2005-2006. 2008. Accessed April 20, 2010 http://www.cdc.gov/nchs/data/hestat/overweight/overweight_adult.pdf.
7. Center for Disease Control and Prevention (CDC). About BMI for children and teens. 2009. Accessed April 24, 2010 http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html.
8. Center for Disease Control and Prevention (CDC). About BMI for adults. 2009. Accessed April 20, 2010 http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html.
9. Anderson P.M., Butcher K.E. Childhood obesity: trends and potential causes. Future Child 2006, 16:19-45.
10. Wang Y., Beydoun M.A. The obesity epidemic in the United States - gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 2007, 29:6-28.
11. Kuntz B., Lampert T. Socioeconomic factors and obesity. Dtsch Arztebl Int 2010, 107:517-522.
12. Quilliot D., Roche G., Mohebbi H., Sirvaux M.A., Bohme P., Ziegler O. Nonsurgical management of obesity in adults. Presse Med 2010, 39:930-944.
13. Robinson T.N. Television viewing and childhood obesity. Pediatr Clin North Am 2001, 48:1017-1025.
14. Yusuf S., Reddy S., Ounpuu S., Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001, 104:2746-2753.
15. Omran A.R. The epidemiologic transition: a theory of the epidemiology of population change, 1971. Milbank Q 2005, 83:731-757.
16. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002, 3:565-574.
17. Mokdad A.H., Ford E.S., Bowman E.S., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
18. McElroy S.L., Kotwal R., Malhotra S., Nelson E.B., Keck P.E., Nemeroff C.B. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004, 65:634-651. [quiz 730].
19. Woolf A.D., Breedveld F., Kvien T.K. Controlling the obesity epidemic is important for maintaining musculoskeletal health. Ann Rheum Dis 2006, 65:1401-1402.
20. Freedman D.S., Dietz W.H., Srinivasan S.R., Berenson G.S. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999, 103:1175-1182.
21. Marcovecchio M., Mohn A., Chiarelli F. Type 2 diabetes mellitus in children and adolescents. J Endocrinol Invest 2005, 28:853-863.
22. James P.T., Rigby N., Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 2004, 11:3-8.
23. Galal O.M., Hulett J. Obesity among schoolchildren in developing countries. Food Nutr Bull 2005, 26:S261-S266.
24. Field A.E., Cook N.R., Gillman M.W. Weight status in childhood as a predictor of becoming overweight or hypertensive in early adulthood. Obes Res 2005, 13:163-169.
25. Nader P.R., O'Brien M., Houts R., et al. Identifying risk for obesity in early childhood. Pediatrics 2006, 118:e594-e601.
26. Herman K.M., Craig C.L., Gauvin L., Katzmarzyk P.T. Tracking of obesity and physical activity from childhood to adulthood: the Physical Activity Longitudinal Study. Int J Pediatr Obes 2009, 4:281-288.
27. Koplan J.P., Liverman C.T., Kraak V.I. Preventing childhood obesity: health in the balance: executive summary. J Am Diet Assoc 2005, 105:131-138.
28. Wolf A.M., Colditz G.A. Current estimates of the economic cost of obesity in the United States. Obes Res 1998, 6:97-106.
29. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. 2010. Accessed July 1, 2011 http://www.nber.org/papers/w16467.
30. Summerbell CD, Waters E, Edmunds LD, Kelly S, Brown T, Campbell LD. Interventions for preventing obesity in children. Cochrane Database Syst Rev 2005;CD001871.
31. Campbell K.J., Hesketh K.D. Strategies which aim to positively impact on weight, Physical activity, diet and sedentary behaviours in children from zero to five years. A systematic review of the literature. Obes Rev 2007, 8:327-338.
32. Hesketh K.D., Campbell K.J. Interventions to prevent obesity in 0-5 year olds: an updated systematic review of the literature. Obesity (Silver Spring) 2010, 18(Suppl 1):S27-S35.
33. Young K.M., Northern J.J., Lister K.M., Drummond J.A., O'Brien W.H. A meta-analysis of family-behavioral weight-loss treatments for children. Clin Psychol Rev 2007, 27:240-249.
34. Seo D.C., Sa J. A meta-analysis of obesity interventions among U.S. minority children. J Adolesc Health 2010, 46:309-323.
35. Lombard C.B., Deeks A.A., Teede H.J. A systematic review of interventions aimed at the prevention of weight gain in adults. Public Health Nutr 2009, 12:2236-2246.
36. Lemmens V.E., Oenema A., Klepp K.I., Henriksen H.B., Brug J. A systematic review of the evidence regarding efficacy of obesity prevention interventions among adults. Obes Rev 2008, 9:446-455.
37. Wing R.R., Tate D.F., Gorin A.A., Raynor H.A., Fava J.L. A self-regulation program for maintenance of weight loss. N Engl J Med 2006, 355:1563-1571.
38. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
39. Caterson I.D., Gill T.P. Obesity: epidemiology and possible prevention. Best Pract Res Clin Endocrinol Metab 2002, 16:595-610.
40. Nielsen S.J., Siega-Riz A.M., Popkin B.M. Trends in energy intake in U.S. between 1977 and 1996: similar shifts seen across age groups. Obes Res 2002, 10:370-378.
41. Cutler D.M., Glaeser E.L., Shapiro J.L. Why have Americans become more obese?. J Econ Perspect 2003, 17:93-118.
42. Ahima R.S., Antwi D.A. Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am 2008, 37:811-823.
43. Banni S., Di Marzo V. Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res 2010, 54:82-92.
44. Artmann A., Petersen G., Hellgren L.I., et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008, 1781:200-212.
45. Matias I., Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007, 18:27-37.
46. Yoshida R., Ohkuri T., Jyotaki M., et al. Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci USA 2010, 107:935-939.
47. Van Gaal L., Pi-Sunyer X., Despres J.P., McCarthy C., Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008, 31(Suppl 2):S229-240.
48. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
49. Fulton S. Appetite and reward. Front Neuroendocrinol 2010, 31:85-103.
50. Reisbick S., Neuringe M. Omega-3 fatty acid deficiency and behavior: a critical review and directions for future research. Handbook of essential fatty acid biology: biochemistry, physiology and behavioral neurobiology 1997, Humana Press, Towota, NJ. S. Yehuda, D.I. Mostofsky (Eds.).
51. Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005, 16:297-313.
52. Figlewicz D.P., Benoit S.C. Insulin, leptin, and food reward: update 2008. Am J Physiol Regul Integr Comp Physiol 2009, 296:R9-R19.
53. Zheng H., Lenard N.R., Shin A.C., Berthoud H.R. Appetite control and energy balance regulation in the modern world: reward-driven brain overrides repletion signals. Int J Obes (Lond) 2009, 33(Suppl 2):S8-S13.
54. Anderson B.M., Ma D.W. Are all n-3 polyunsaturated fatty acids created equal?. Lipids Health Dis 2009, 8:33.
55. Wang C., Harris W.S., Chung M., et al. n-3 fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006, 84:5-17.
56. Skerrett P.J., Hennekens C.H. Consumption of fish and fish oils and decreased risk of stroke. Prev Cardiol 2003, 6:38-41.
57. Amminger G.P., Schafer M.R., Papageorgiou K., et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010, 67:146-154.
58. Ross B.M., Seguin J., Sieswerda L.E. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. Lipids Health Dis 2007, 6:21-25.
59. Wall R., Ross R.P., Fitzgerald G.F., Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010, 68:280-289.
60. Carpentier Y.A., Portois L., Malaisse W.J. n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr 2006, 83:1499S-1504S.
61. Schuchardt J.P., Huss M., Stauss-Grabo M., Hahn A. Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr 2010, 169:149-164.
62. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and Cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
63. Watanabe S., Doshi M., Hamazaki T. n-3 polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 2003, 69:51-59.
64. Di Marzo V., Griinari M., Carta G., et al. Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. Int Dairy J 2010, 20:231-235.
65. D'Asti E., Long H., Tremblay-Mercier J., et al. Maternal dietary fat determines metabolic profile and the magnitude of endocannabinoid inhibition of the stress response in neonatal rat offspring. Endocrinol 2010, 151:1685-1694.
66. Chalon S., Vancassel S., Zimmer L., Guilloteau D., Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids 2001, 36:937-944.
67. Fedorova I., Salem N. Omega-3 fatty acids and rodent behavior. Prostaglandins Leukot Essent Fatty Acids 2006, 75:271-289.
68. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006, 75:259-269.
69. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 2008, 45:19-25.
70. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Press; 1994.
71. Tripp G., Wickens J.R. Neurobiology of ADHD. Neuropharmacology 2009, 57:579-589.
72. Del Campo N., Chamberlain S.R., Sahakian B.J., Robbins T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 2011, 69:e145-e157. [ePUB].
73. Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol 2008, 28:S39-45.
74. Faraone S.V., Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998, 44:951-958.
75. Chalon S. The role of fatty acids in the treatment of ADHD. Neuropharmacology 2009, 57:636-639.
76. Laviolette S.R. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?. Schizophr Bull 2007, 33:971-981.
77. Buckley J.D., Howe P.R. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. Obes Rev 2009, 10:648-659.
78. Hainault I., Carolotti M., Hajduch E., Guichard C., Lavau M. Fish oil in a high lard diet prevents obesity, hyperlipemia, and adipocyte insulin resistance in rats. Ann N Y Acad Sci 1993, 683:98-101.
79. Baillie R.A., Takada R., Nakamura M., Clarke S.D. Coordinate induction of peroxisomal acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for decreased body fat deposition. Prostaglandins Leukot Essent Fatty Acids 1999, 60:351-356.
80. Belzung F., Raclot T., Groscolas R. Fish oil n-3 fatty acids selectively limit the hypertrophy of abdominal fat depots in growing rats fed high-fat diets. Am J Physiol 1993, 264:R1111-R1118.
81. Parrish C.C., Pathy D.A., Angel A. Dietary fish oils limit adipose tissue hypertrophy in rats. Metabolism 1990, 39:217-219.
82. Perez-Matute P., Perez-Echarri N., Martinez J.A., Marti A., Moreno-Aliaga M.J. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-alpha. Br J Nutr 2007, 97:389-398.
83. Ruzickova J., Rossmeisl M., Prazak T., et al. Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 2004, 39:1177-1185.
84. Huang X.F., Xin X., McLennan P., Storlien L. Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab 2004, 6:35-44.
85. Takahashi Y., Ide T. Dietary n-3 fatty acids affect mRNA level of brown adipose tissue uncoupling protein 1, and white adipose tissue leptin and glucose transporter 4 in the rat. Br J Nutr 2000, 84:175-184.
86. Hassanali Z., Ametaj B.N., Field C.J., Proctor S.D., Vine D.F. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diabetes Obes Metab 2010, 12:139-147.
87. Mathai M.L., Soueid M., Chen N., et al. Does perinatal omega-3 polyunsaturated fatty acid deficiency increase appetite signaling?. Obes Res 2004, 12:1886-1894.
88. Shashoua V.E., Hesse G.W. N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci 1996, 58:1347-1357.
89. Cha S.H., Fukushima A., Sakuma K., Kagawa Y. Chronic docosahexaenoic acid intake enhances expression of the gene for uncoupling protein 3 and affects pleiotropic mRNA levels in skeletal muscle of aged C57BL/6NJcl mice. J Nutr 2001, 131:2636-2642.
90. Food and Drug Administration (FDA). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005, Accessed April 1, 2011 http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078932.pdf.
91. Kris-Etherton P.M., Taylor D.S., Yu-Poth S., et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000, 71:179S-188S.
92. Food and Drug Administration (FDA). Substances affirmed as generally recognized as safe: menhaden oil. Fed Reg 1997;62:30751-7.
93. Micallef M., Munro I., Phang M., Garg M. Plasma n-3 polyunsaturated fatty acids are negatively associated with obesity. Br J Nutr 2009, 102:1370-1374.
94. Klein-Platat C., Drai J., Oujaa M., Schlienger J.L., Simon C. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr 2005, 82:1178-1184.
95. Scaglioni S., Verduci E., Salvioni M., et al. Plasma long-chain fatty acids and the degree of obesity in Italian children. Acta Paediatr 2006, 95:964-969.
96. Kabir M., Skurnik G., Naour N., et al. Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007, 86:1670-1679.
97. Thorsdottir I., Tomasson H., Gunnarsdottir I., et al. Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int J Obes (Lond) 2007, 31:1560-1566.
98. Parra D., Ramel A., Bandarra N., Kiely M., Martinez J.A., Thorsdottir I. A diet rich in long chain omega-3 fatty acids modulates satiety in overweight and obese volunteers during weight loss. Appetite 2008, 51:676-680.
99. Flachs P., Rossmeisl M., Bryhn M., Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond) 2009, 116:1-16.
100. Hill J.O. Can a small-changes approach help address the obesity epidemic? A report of the joint task force of the American Society for Nutrition, Institute of Food Technologists, and International Food Information Council. Am J Clin Nutr 2009, 89:477-484.
101. Davidson M.H., Stein E.A., Bays H.E., et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4g/d to simvastatin 40mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29:1354-1367.